

JANUARY

Date	Headline and Source	Link	Summary
2 nd January	India's healthcare on fast-track growth trajectory Fortune, January 02, 2025	India's healthcare on fast-track growth trajectory	India's disease profile has shifted significantly in the last two decades. Noncommunicable Diseases (NCD) now account for over 65% of the disease burden and the country has a large and ageing population with 100 million plus elderly people (about 7% of the population), says Winning in Indian Healthcare, a recent report brought out by the Boston Consulting Group (BCG) and the Organisation of Pharmaceutical Producers of India (OPPI).
2 nd January	Drug firms amp up hiring for top roles as growth beckons MINT, January 02, 2025	Drug firms amp up hiring for top roles as growth beckons	India's pharmaceuticals industry which was worth \$50 billion in FY24 is poised to grow to \$130 billion by 2030, a joint report by EY-Parthenon and the Organisation of Pharmaceutical Producers of India (OPPI) showed aided by growing domestic market and exports. Companies are focusing more on innovation, complex generics, biosimilars, and new chemical entities to boost exports, the report noted.
2 nd January	32,000 scans for cancer detection completed under AstraZeneca-DHS Goa partnership: Vishwajit Goemkarponn, January 02, 2025	32,000 scans for cancer detection completed under AstraZeneca-DHS Goa partnership: Vishwajit	With 32,000 scans completed under the AstraZeneca-DHS Goa partnership, Health Minister Vishwajit Rane said that the state is making significant strides in early cancer detection. Rane said that this initiative aligns with the vision of our PM Narendra Modi, who, during his #MannKiBaat address, highlighted the importance of timely treatment.
4 th January	What's in store for pharmaceutical sector in 2025 The Financial Express, January 04, 2025	What's in store for pharmaceutical sector in 2025	Milestone initiatives such as the expansion of the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) and the PRIP scheme to boost domestic manufacturing of key starting materials (KSMs) and APIs, reflected the government's commitment to building an inclusive healthcare ecosystem in 2024, Anil Matai, Director General, Organisation Of Pharmaceutical Producers of India (OPPI) told Financial Express.com.
4 th January	Pharma firms seek booster shot to PLI Business Standard, January 04, 2025	Pharma firms seek booster shot to PLI	Commenting on the industry's expectations, Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI), which represents multinational pharma companies working in India, said that policy-level clarifications, such as expanded exemptions for lifesaving drugs and

			oncology medications from import duty, are vital for reducing treatment costs. (IPA)
4 th January	OPPI seeks policy level clarifications for reducing treatment costs from Budget 2025 Bio Spectrum, January 04, 2025	OPPI seeks policy level clarifications for reducing treatment costs from Budget 2025	OPPI highlights Budget Predictions and Recommendations To strengthen India's healthcare ecosystem and drive inclusive growth, the upcoming budget must prioritize increased public spending on health initiatives. This includes expanding coverage under the Ayushman Bharat scheme to missing middle, upgrading existing Centres of Excellence, establishing new ones, and enhancing primary healthcare infrastructure.
5 th January	CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ruxolitinib study Medical Dialogues, January 05, 2025	CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ruxolitinib study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by Novartis to study anticancer drug INC424 (Ruxolitinib).
6 th January	CDSCO Panel approves Novartis Protocol Amendment Proposal For TIN816 study in Sepsis-associated Acute Medical Dialogues, January 06, 2025	CDSCO Panel approves Novartis Protocol Amendment Proposal For TIN816 study in Sepsis-associated Acute	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the protocol amendment proposal presented by Novartis for the renal drug TIN816 study.
6 th January	CDSCO panel approves Sanofi's proposal to increase number of subjects from 25 to 40 in India to study SAR443122 Medical Dialogues, January 06, 2025	CDSCO panel approves Sanofi's proposal to increase number of subjects from 25 to 40 in India to study SAR443122	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major Sanofi in the Ulcerative Colitis Studies of SAR443122 to increase the number of subjects from India from 25 to 40 subjects with the condition that more government sites shall be included in the study and enrollment from government sites shall be increased.
7 th January	Budget 2025: OPPI seeks special incentives Bio Voice News, January 07, 2025	Budget 2025: OPPI seeks special incentives	"To strengthen India's healthcare ecosystem and drive inclusive growth, the upcoming budget must prioritize increased public spending on health initiatives. This includes expanding coverage under the Ayushman Bharat scheme to missing middle, upgrading existing Centers of Excellence, establishing new ones, and enhancing primary healthcare infrastructure," stated Anil Matai, Director General, OPPI.
7 th January	Bayer aims to expand presence in India with new therapies and strategic collaborations Business Today, January 07, 2025	Bayer aims to expand presence in India with new therapies and strategic collaborations	German multinational pharmaceutical and biotechnology company Bayer is seeking to strengthen its presence in India by expanding its portfolio of therapies and enhancing collaborations across the healthcare ecosystem.

8 th January	Association leaders share their expectations from Budget 2025-26 Express Pharma, January 08, 2025	Association leaders share their expectations from Budget 2025-26	Anil Matai, Director General, OPPI To strengthen India's healthcare ecosystem and drive inclusive growth, the upcoming budget must prioritise increased public spending on health initiatives. This includes expanding coverage under the Ayushman Bharat scheme to the missing middle, upgrading existing Centers of Excellence, establishing new ones, and enhancing primary healthcare infrastructure.
8 th January	Budget 2025: Pharma Sector Calls for Tax Breaks, R&D Support, and Patent Box Overhaul ET Pharma, January 08, 2025	Budget 2025: Pharma Sector Calls for Tax Breaks, R&D Support, and Patent Box Overhaul	Highlighting other demands, Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) said, "Expanding the scope of Section 115BAB of the Income Tax Act, 1961, to companies solely engaged in pharmaceutical R&D will encourage innovation in the pharma space."
9 th January	US pharma major Eli Lilly to set up GCC in Hyd The Times of India, January 09, 2025	US pharma major Eli Lilly to set up GCC in Hyd	The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is growing longer. After pharma and biopharma biggies such as Amgen, Sanofi, Novartis, Bristol Myers Squibb, and Zoetis, the city is now learnt to be on the radar of pharma giants such as Eli Lilly, GSK, and Merck.
10 th January	Budget 2025: Tax cuts, sops on Pharma Inc's wish list The Economic Times, January 10, 2025	Budget 2025: Tax cuts, sops on Pharma Inc's wish list	Organisation of Pharmaceutical Producers of India director-general Anil Matai urged the government to explore methods to incentivise R&D investments, such as tax deductions on R&D expenses, research-linked incentives for multinationals and corporate tax concessions to accelerate.
10 th January	Pfizer Gets CDSCO Panel Nod To Study Anticancer Drug PF07220060 Medical Dialogues, January 10, 2025	Pfizer Gets CDSCO Panel Nod To Study Anticancer Drug PF07220060	The drug major Pfizer has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase III clinical trial of the anticancer drug PF07220060 100 mg immediate release (IR) tablets.
10 th January	Eli Lilly to set up global capability centre in Hyderabad, hire 1K people Business Standard, January 10, 2025	Eli Lilly to set up global capability centre in Hyderabad, hire 1K people	The Hyderabad global capability centre (GCC) will be known as Lilly Capability Centre India (LCCI) Hyderabad and will initially focus on expanding Lilly's capabilities in automation, artificial intelligence, software product engineering and cloud computing to deliver advanced technology solutions that meet the evolving needs of Lilly's business worldwide, the Eli Lilly and Company (Lilly) said in a statement.

11 th January	Pharma and Hospital Executives Push for Key Demands in Union Budget 2025 India Pharma Outlook, January 11, 2025	Pharma and Hospital Executives Push for Key Demands in Union Budget 2025	Organisation of Pharmaceutical Producers of India director general Anil Matai called on the government to investigate ways to encourage R&D investments, including tax breaks on R&D costs, incentives linked to research for multinationals, and corporate tax reductions to hasten progress.
12 th January	Fake cancer medicines coming from Bangladesh are spreading like wildfire in India Aaj Tak, January 12, 2025	Fake cancer medicines coming from Bangladesh are spreading like wildfire in India	Due to lack of information, State Insurance Corporation and many other government institutions also buy such medicines for patients. According to the report, the Organization of Pharmaceutical Producers of India (OPPI) has complained about this to the government, after which the central government has assured to take action on it.
13 th January	Hyderabad to get Eli Lilly global capability centre Medical Dialogues, January 13, 2025	Hyderabad to get Eli Lilly global capability centre	Eli Lilly and Company is planning to set up a new global capability centre in Hyderabad. This will be the Company's second such site in India, following the launch of the Lilly Capability Center India (LCCI) in Bengaluru in 2016, the company said.
16 th January	Japan's Takeda to hire 750 in India to boost deep tech The Hindu, January 16, 2025	Japan's Takeda to hire 750 in India to boost deep tech	Takeda, a Japanese biopharmaceutical firm, on Wednesday said it would hire 750 deep-tech professionals in calendar 2025 to be deployed at its newly set-up Innovation Capability Centre in Bengaluru. The company had already hired 270 software developers, scrum masters, AI specialists and data analysts, a spokesperson said.
17 th January	AstraZeneca's Eculizumab becomes first CDSCO-approved anticomplement medicine to manage two rare diseases BioSpectrum India, January 17, 2025	AstraZeneca's Eculizumab becomes first CDSCO-approved anticomplement medicine to manage two rare diseases	AstraZeneca Pharma India has announced a Central Drugs Standard Control Organisation (CDSCO) permission to import, sale or distribute Eculizumab concentrate solution for infusion 300 mg (10mg/ml). Through this approval, Eculizumab becomes a first anticomplement medical therapy indicated for treating two rare conditions Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS), both in children and adults.
17 th January	Takeda unveils innovation centre in Bengaluru, to hire 750 people The Times of India, January 17, 2025	Takeda unveils innovation centre in Bengaluru, to hire 750 people	Japanese biopharmaceutical company Takeda opened an innovation capability centre (ICC) in Bengaluru, leveraging the city's tech talent pool to build core digital skills inhouse This flagship facility joins the company's existing centres in Slovakia and Mexico, which together employ about 650 people
19 th January	Indian pharma hopes for policy-level clarifications & simplifying APA procedures	Indian pharma hopes for policy-level clarifications & simplifying	Representing the sector of researchbased global pharmaceutical companies in India, Anil Matai, director general, Organisation of

	in Union Budget 2025 PharmaBiz, January 19, 2025	APA procedures in Union Budget 2025	Pharmaceutical Producers of India (OPPI), said the need of the hour is policy-level clarifications, such as expanded exemptions for lifesaving drugs and oncology medications from import duty which are vital for reducing treatment costs.
19 th January	First anti-complement therapy for rare diseases gets CDSCO approval in India - Healthcare Radius Health Care Radius, January 19, 2025	First anti-complement therapy for rare diseases gets CDSCO approval in India - Healthcare Radius	AstraZeneca Pharma India Limited, a science-led biopharmaceutical company, announced a Central Drugs Standard Control Organisation (CDSCO) permission to import, sale or distribute 'Eculizumab' concentrate solution for infusion 300 mg (10mg/ml).
20 th January	CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Retatrutide study Medical Dialogues, January 20, 2025	CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Retatrutide study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by drug major Eli Lilly for Retatrutide study. This came after the firm presented a protocol amendment dated 19 September 2024 protocol no. J1I-MC-GZBO.
21 st January	Budget 2025: Pharma industry lays out a plan to curb Chinese dependence The Economic Times, January 21, 2025	Budget 2025: Pharma industry lays out a plan to curb Chinese dependence	Anil Matai, Director General of the Organisation of Pharmaceutical Producers of India (OPPI), stresses that targeted investments are urgently needed to ensure the competitiveness of new chemical entities. Simplifying the process of obtaining regulatory approvals will also enhance the sector's competitiveness.
23 rd January	Sanofi Healthcare India gets CDSCO Panel nod to study Nirsevimab Medical Dialogues, January 23, 2025	Sanofi Healthcare India gets CDSCO Panel nod to study Nirsevimab	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major Sanofi Healthcare India to conduct a Phase IV clinical trial of Nirsevimab.
23 rd January	CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal for Anticancer Drug Volrustomig study Medical Dialogues, January 23, 2025	CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal for Anticancer Drug Volrustomig study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by the drug major AstraZeneca Pharma India for Volrustomig (MEDI5752) study.
25 th January	Budget 2024: These companies can get the benefit of concessional tax rates CNBC TV18, January 25, 2024	Budget 2024: These companies can get the benefit of concessional tax rates	Anil Matai, Director General of Organization of Pharmaceutical Producers of India (OPPI) believes that the concessional tax rates under Section 115BAB of the Income Tax Act, 1961 should be extended to companies engaged in research and development of pharma apart from manufacturing.
25 th January	Swiss healthcare company Roche inaugurates its new	Swiss healthcare company Roche inaugurates its new	Roche opens Digital Centre of Excellence in Pune to leverage the developed Indian and

	campus for its Digital Centre of Excellence in Pune CXO Today, January 25, 2024	campus for its Digital Centre of Excellence in Pune	global digital ecosystem and top talent to build innovative healthcare solutions. The campus can accommodate nearly 1,300 professionals dedicated to working on the latest technologies relevant for our healthcare business.
28 th January	AstraZeneca gets CDSCO Panel nod to study Palivizumab solution for injection Medical Dialogues, January 28, 2025	AstraZeneca gets CDSCO Panel nod to study Palivizumab solution for injection	Citing that clinical trial sites should be geographically distributed, including government sites, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major AstraZeneca to conduct the study of Palivizumab solution for injection 50 mg/0.5 mL and 100 mg/mL.
28 th January	Merck inaugurates the expansion of its Peenya facility in Bengaluru Express Pharma, January 28, 2025	Merck inaugurates the expansion of its Peenya facility in Bengaluru	Merck Life Science in India has recently announced the expansion of its manufacturing facility in Peenya, Bengaluru. The expansion will transform Peenya into a key manufacturing hub for Merck in the APAC region. Merck hosted an inaugural ceremony at the Peenya site, bringing together company leadership, customers and key stakeholders.
29 th January	Merck Life Science and DPIIT MoU aims to empower biotech startups Express Pharma, January 29, 2025	Merck Life Science and DPIIT MoU aims to empower biotech startups	In line with DPIIT's mission of fostering innovation and enabling industrial growth, is its partnership with Merck Life Science, which provides emerging biotech innovators with access to mentorship, market linkages, and cutting-edge global technologies.
